New product newswire: August 21, 2006

News
Article

AstraZeneca, Wilmington, Del., (800) 842-9920, has received FDA approval for Symbicort (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol. The new inhaler is indicated for long-term maintenance treatment of asthma in patients 12 years of age and older.

Related Content
FDA Grants Tovorafenib Approval to Treat Relapsed or Refractory Pediatric Low-Grade Glioma

FDA Grants Tovorafenib Approval to Treat Relapsed or Refractory Pediatric Low-Grade Glioma

April 23rd 2024
Article

The approval for tovorafenib (Ojemda) was based on data from the phase 2 FIREFLY-1 trial, in which the therapy demonstrated an overall repose rate of 67%.

Over the Counter podcast

Episode 8: Stay in Sync with Innovations in Medication Decision Support

August 6th 2020
Podcast

Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space.

FDA Roundup: Biosimilars, Boxed Warning Added for CAR T-Cell Therapies

FDA Roundup: Biosimilars, Boxed Warning Added for CAR T-Cell Therapies

April 19th 2024
Article

Check out important updates from the FDA for the week of April 15.

Stelara Biosimilar Ustekinumab-aekn Recieves FDA Approval

Stelara Biosimilar Ustekinumab-aekn Recieves FDA Approval

April 19th 2024
Article

This approval is the second biosimilar approval for manufacturer Alvotech.

FDA Accepts GSK's BLA for 5-in-1 Meningococcal Vaccine

FDA Accepts GSK's BLA for 5-in-1 Meningococcal Vaccine

April 16th 2024
Article

The company’s investigational ABCWY vaccine candidate will be reviewed by the FDA by February 14, 2025.

Rx Roundup: Quiz of the Week — April 12, 2024

Rx Roundup: Quiz of the Week — April 12, 2024

April 12th 2024
Article

Test your pharmacy news knowledge with our weekly quiz.

© 2024 MJH Life Sciences

All rights reserved.